Medical Advocates
HIV Infection/Disease
  Pre-Exposure Prophylaxis

General Reports
 Special Populations
 Ethical Challenges
Drugs




 
HIV Prevention Main Page Main New/Newsworthy Home Page

Last Update:  November 25, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
     
          Internet Documents
 
  FULL-TEXT DOCUMENT
 Fact Sheet: CDC Trials of Daily Oral Tenofovir for Preventing HIV Infection
 CDC
January 3, 2005
Document
 
            Journal Papers, Abstracts, and Commentaries    
 
 
Nonoccupational Postexposure Prophylaxis for Exposure to HIV in New York State Emergency
Departments.
 Ende AR, Hein L, Sottolano DL, Agins BD. 
AIDS Patient Care STDS. 2008 Sep 18.
Abstract
 
Antiretrovirals to Prevent HIV Infection: Pre- and Postexposure Prophylaxis.
Gay CL, Cohen MS.  
Curr Infect Dis Rep. 2008 Jul;10(4):323-31.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 We Must Not Let Protestors Derail Trials of Pre-Exposure Prophylaxis for HIV
Lange JMA
 PLOS MedicineVol2 Issue 9 Sep 2005
 Paper
 
FULL-TEXT ARTICLE
 The Abandoned Trials of Pre-Exposure Prophylaxis for HIV: What Went Wrong?
Singh J,  Mills EJ
 PLOS Medicine Vol2 Issue 9 Sep 2005
 Paper
 
FULL-TEXT ARTICLE
Media reporting of tenofovir trials in Cambodia and Cameroon.
Mills E, Rachlis B, Wu P, et al
BMC Int Health Hum Rights.  2005 Aug 24;5:6.
 Paper
 
FULL-TEXT ARTICLE
Pre-exposure chemoprophylaxis for HIV: it is time.
Smith SM.
Retrovirology. 2004 Jul 6;1(1):16.
 Paper
 
 
              Conference Reports, Abstracts, and Posters 
 
 
What is the role of community advocacy in future pre-exposure prophylaxis (PrEP) research?
Halima Y, Kort R
 (4th IAS Conference)
 Abstract
 
Antiretroviral therapy for prevention of transmission of HIV-1
 MS Cohen
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Antiretroviral Therapy to Prevent Sexual Transmission of HIV
M Cohen 
(13 CROI)
 Abstract
 
Cost-effectiveness Analysis of ART for Pre-exposure Prophylaxis
A Hill, M Youle, C Boucher 
(13 CROI)
 Abstract
Special Populations
     
Discordant Couples
 
     Conference Reports, Abstracts, and Posters
 
  Pre-exposure prophylaxis and timed intercourse for HIV-discordant couples willing to
conceive a child
Vernazza P, Brenner I, Graf I, et al
 (4th IAS Conference)
 Abstract
 
MSM
     Conference Reports, Abstracts, and Posters
 
 
Oral or rectal chemoprophylaxis to prevent HIV transmission: what do at risk men who have sex
with men (MSM) know and want?
Mayer K, Dolezal C, Carballo-Dieguez A, et al
 (4th IAS Conference)
 Abstract
 
Willingness to participate in a HIV pre-exposure prophylaxis efficacy trial among high risk men who
have sex with men in the Andean region
 Lama JR, Guanira J, Goicochea P
 (4th IAS Conference)
 Abstract
 
Modeling the potential impact of HIV chemoprophylaxis strategies among men who have sex with
men in the United States: HIV infections prevented and cost-effectiveness
Desai K., McGreevey W.P., Ackers M.L., et al
 (XVI International AIDS Conference)
 Abstract

Low levels of pre-exposure prophylaxis awareness and use among HIV-negative/unknown gay/
bisexual men: San Francisco Bay Area residents, circuit party attendees, and clients of an urban
STD clinic
A. Liu, S. Wheeler, E. Vittinghoff, et al 
(XVI International AIDS Conference)
 Abstract

HIV Pre- and Post- Exposure Prophylaxis Among Bathhouse Patrons
DDaskalakis, K T. Bernstein, R Hagerty, et al 
(2006 National STD Prevention Conference0
 Abstract
 
Knowledge and Use of Pre-Exposure Prophylaxis Among Attendees of Minority Gay
Pride Events, 2004
Kellerman S., Hutchinson A., Begley E., et al
 ($rd IAS)
 Abstract
 
Sexworkers

     Conference Reports, Abstracts, and Posters

 
Factors influencing adherence to pills for pre-exposure prophylaxis: lessons learned from a phase
2 trial
Lawoyin T., Alleman P., Guest G., MacQueen K.
 (XVI International AIDS Conference)
 Abstract
Ethical Challenges
     

     Journal Papers, Abstracts, and Commentaries 

  Tenofovir trials raise ethical issues.
Mills E.
HIV AIDS Policy Law Rev. 2005 Aug;10(2):31-2.
 Abstract
Drugs
     
Nevirapine

     Journal Papers, Abstracts, and Commentaries 
 
  A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission
in uninfected subjects at high risk.
 Jackson JB, Barnett S, Piwowar-Manning E, et al.
AIDS 2003 Mar 7;17(4):547-53
 Abstract
 
Tenofovir

      Journal Papers, Abstracts, and Commentaries 
 
 
FULL TEXT ARTICLE
 Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2,
Double-Blind,Randomized, Placebo-Controlled Trial.
Peterson L, Taylor D, Roddy R, et al
PLoS Clin Trials. 2007 May 25;2(5):e27.
 Paper

Tenofovir trials raise ethical issues.
Mills E.
HIV AIDS Policy Law Rev. 2005 Aug;10(2):31-2.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
 
Factors influencing adherence to pills for pre-exposure prophylaxis: lessons learned from a phase
2 trial
Lawoyin T., Alleman P., Guest G., MacQueen K.
 XVI International AIDS Conference)
 Abstract
 
HIV prevention using tenofovir: community participation in the formative phase of a HIV prevention
trial in Cambodia
Pisith P., Roberts J., Sim S.,  et al
 (XVI International AIDS Conference)
 Abstract
 
Addressing HIV prevention trial challenges through sociobehavioral research: Cameroon’s tenofovir
trial
Nyiama T.A., Mack N., MacQueen K., et al
 (XVI International AIDS Conference)
 Abstract
 
Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana:
a simple mathematical modelling approach
Smith D., Kebaabetswe P., Disasi K., et al
 (XVI International AIDS Conference)
 Abstract
 
Participant experiences of the tenofovir HIV prevention trial in Nigeria and Cameroon: implications
for recruitment and retention
Guest G., Alleman P., Lawoyin T., et al
 (XVI International AIDS Conference)
 Abstract
 
Overcoming the challenges of prevention research: lessons learned from the tenofovir pre-exposure
prophylaxis trials
Halima Y.
(XVI International AIDS Conference)
 Abstract
 
Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana:
a simple mathematical modelling approach
 Smith D., Kebaabetswe P., Disasi K., et al
 (XVI International AIDS Conference)
 Abstract
 
Findings from a double-blind, randomized, placebo-controlled trial of tenofovir disoproxil fumarate
(TDF) for prevention of HIV infection in women
 L. Peterson, D. Taylor, EEK. Clarke, et al 
(XVI International AIDS Conference)
 Abstract

HIV Prevention Main Page Main New/Newsworthy Home Page

HIV Infection/Disease:
Pre-Exposure Prophylaxis